(via TheNewswire)
 |
|||||||||
 |
 |
 |
|||||||
Winnipeg, May 27, 2024. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”), the only publicly traded phage company that is focused on bacteriophage solutions for both animal health and human health, is pleased to announce that it has strengthened its board of directors with the addition of John Snisarenko, a 30+ year veteran of, and seasoned C-Suite executive in, the pharmaceutical and biotech industries.
Chairman of the Cytophage board, Harold Wolkin, commented: “We continue to add depth to our board, and that is really a reflection of the ambition of our team and what we are looking to accomplish over the coming months. John is a most welcome addition to our team, and his multi-faceted experience with pharmaceuticals and biotech will be invaluable in guiding Cytophage’s product commercialization efforts.”
During his 30+ years in pharmaceutical and biotech industries, John Snisarenko focused on ophthalmology and eye care. John’s most recent position was Chief Commercial Officer for Oyster Point Pharma, where he led the launch planning, infrastructure building and commercial launch for Tyrvaya. Prior to Oyster Point, John served as Group Vice President and Head of the Ophthalmics Franchise at Shire (now Takeda), where he led a large, multidisciplinary team in the commercialization of Xiidra. He also served as a member of the Shire Commercial Leadership Team. Previously, John was the VP & Franchise Head responsible for the commercial activities within Genentech’s Ophthalmology (Lucentis) and Rheumatology (Rituxan, Actemra) franchises for 10 years. All three medicines achieved over $1B in sales in the U.S. marketplace.
John also held various positions of increasing responsibility at CIBA Vision / Novartis Pharma Canada. In his last 9 years there, he served as VP and Business Unit Head for Novartis Ophthalmics, holding general management responsibilities for the Canadian business.
John holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada. He is currently serving as an Independent Director, Board Member and Advisor to many start-up and established companies in both Canada and the United States.
“With the increasing threat of antimicrobial resistance (“AMR”) to global health, I am honoured to join the board of a true pioneer in bacteriophage solutions such as Cytophage”, commented John Snisarenko on his appointment. “I am excited to bring my 30+ years of commercialization experience to the Cytophage board, and as the inaugural chair of their Commercialization Committee, I am very much looking forward to lending my skills to getting their products into the marketplace.”
For further information please contact:
Heather Medwick
Chief Operating Officer
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies (TSXV:CYTO) is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Cautionary Statement on Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are
described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
Copyright (c) 2024 TheNewswire – All rights reserved.
COMTEX_452964164/2895/2024-05-27T07:52:42